Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. Fundamental Analysis
Apellis Pharmaceuticals, Inc. (APLS) shows moderate financial fundamentals with a PE ratio of 38.80, profit margin of 12.95%, and ROE of 39.71%. The company generates $1.0B in annual revenue with strong year-over-year growth of 28.46%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 77.4/100 based on profitability, valuation, growth, and balance sheet metrics. The B grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze APLS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentAPLS demonstrates superior asset utilization.
Valuation Score
ModerateAPLS shows balanced valuation metrics.
Growth Score
ModerateAPLS shows steady but slowing expansion.
Financial Health Score
ExcellentAPLS maintains a strong and stable balance sheet.
Profitability Score
ModerateAPLS maintains healthy but balanced margins.
Key Financial Metrics
Is APLS Expensive or Cheap?
P/E Ratio
APLS trades at 38.80 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, APLS's PEG of 0.08 indicates potential undervaluation.
Price to Book
The market values Apellis Pharmaceuticals, Inc. at 12.46 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 31.35 times EBITDA. This signals the market has high growth expectations.
How Well Does APLS Make Money?
Net Profit Margin
For every $100 in sales, Apellis Pharmaceuticals, Inc. keeps $12.95 as profit after all expenses.
Operating Margin
Core operations generate 16.06 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $39.71 in profit for every $100 of shareholder equity.
ROA
Apellis Pharmaceuticals, Inc. generates $12.31 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Apellis Pharmaceuticals, Inc. generates limited operating cash flow of $38.37M, signaling weaker underlying cash strength.
Free Cash Flow
Apellis Pharmaceuticals, Inc. produces free cash flow of $38.38M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.30 in free cash annually.
FCF Yield
APLS converts 0.72% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
38.80
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.08
vs 25 benchmark
P/B Ratio
Price to book value ratio
12.46
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.11
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.27
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.63
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.40
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
0.21
vs 25 benchmark
How APLS Stacks Against Its Sector Peers
| Metric | APLS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 38.80 | 29.94 | Worse (Expensive) |
| ROE | 39.71% | 738.00% | Weak |
| Net Margin | 12.95% | -575975.00% (disorted) | Strong |
| Debt/Equity | 0.27 | 0.44 | Strong (Low Leverage) |
| Current Ratio | 3.63 | 4.49 | Strong Liquidity |
| ROA | 12.31% | -15756.00% (disorted) | Strong |
APLS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Apellis Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
138.85%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
103.87%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
116.84%
Industry Style: Defensive, Growth, Innovation
High Growth